Key Highlights
- The third-quarter net loss narrowed to USD 5.6 million from USD 8.7 million, or USD 0.56 per share versus USD 1.01, with total operating expenses falling to USD 5.9 million from USD 9.3 million.
- Unrestricted cash and cash equivalents were USD 20.6 million on September 30, 2026, and the filing states the company expects existing resources to likely be insufficient for the next 12 months.
- Research and development expense fell 37% to USD 3.4 million, while general and administrative expense dropped 35% to USD 2.5 million as Patent litigation costs eased.
- Cash used in Operating Activities for the nine months rose to USD 24.7 million from USD 19.2 million, and the accumulated Deficit stood at USD 270.3 million.
Lower Trial and Legal Costs Narrow the Third-Quarter Loss
Atossa Therapeutics (NASDAQ:ATOS) filed its Quarterly Report on November 10, 2026, showing a third-quarter net loss of USD 5.6 million against USD 8.7 million. The company has no revenue, so the loss tracks spending. Clinical and non-clinical trial costs fell to USD 2.5 million from USD 4.3 million because enrollment in its (Z)-endoxifen studies was largely completed during the first nine months of 2026. General and administrative expense dropped to USD 2.5 million, helped by USD 0.8 million lower legal fees after patent litigation matters were resolved in the first half. Interest income eased by USD 0.4 million to USD 0.2 million on lower average cash balances.
Nine-Month Cash Burn Versus a USD 20.6 Million Cash Balance
The company is a clinical-stage biopharmaceutical developer focused on breast cancer, and its lead candidate, oral (Z)-endoxifen, is in Phase 2 development. For nine months, the net loss of USD 23.7 million was nearly flat on USD 23.8 million, but operating cash outflow rose to USD 24.7 million from USD 19.2 million, mainly on professional fees tied to the settled patent cases and higher trial and drug-development spending. Cash fell to USD 20.6 million with Working Capital of USD 20.5 million. The filing also records substantial doubt about the company's ability to continue as a Going Concern and says the company will need additional capital, which it plans to raise through Equity sales or short-term borrowing.
June Offering, Warrants and the At-the-Market Program
In June 2026, the company sold 1,363,637 shares alongside Series A and Series B warrants in a registered direct offering at a combined USD 3.30, raising net proceeds of USD 4.0 million. The warrants carry an exercise price of USD 4.40 and become exercisable six months after issuance. A USD 50.0 million at-the-market program signed in February 2026 produced only USD 21 thousand of net proceeds in the nine months. Equity raises add shares, which is visible in the weighted share count of 10.0 million versus 8.6 million. Small-cap biotech shares can move sharply on few trades, spreads can be wide and quoted moves can reverse, so the funding path is a central risk for Atossa Therapeutics (NASDAQ:ATOS).
Where Things Stand
The filing says no, or at least not with certainty: it expects existing resources to likely be insufficient for the next 12 months. Atossa Therapeutics (NASDAQ:ATOS) narrowed its quarterly loss by cutting trial and legal spending, but cash of USD 20.6 million is set against a nine-month operating outflow of USD 24.7 million, and the notes record substantial doubt about continuing as a going concern. The company says it will need more capital, which could mean further dilution. Watch for additional financing, progress in the endoxifen studies and whether spending stays near the third-quarter level of USD 5.9 million.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...